Bridgeway Capital Management’s Cabaletta Bio CABA Stock Holding History

Bridgeway Capital Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$832K	Hold	267,372	–	–	0.01%	769
2026 Q1	$719K	Buy	267,372 +136,697	+105%	+$380K	0.01%	764
2025 Q4	$286K	Buy	130,675 +35,000	+37%	+$86.7K	0.01%	944
2025 Q3	$224K	Buy	95,675 +50,000	+109%	+$85.8K	﹤0.01%	993
2025 Q2	$69.4K	Hold	45,675	–	–	﹤0.01%	1111
2025 Q1	$63.3K	Sell	45,675 -42,000	-48%	-$89.5K	﹤0.01%	1102
2024 Q4	$199K	Buy	+87,675	New	+$308K	﹤0.01%	1011
2024 Q1	–	Sell	-46,021	Closed	-$1.04M	–	1315
2023 Q4	$1.04M	Sell	46,021 -4,600	-9%	-$77.3K	0.02%	745
2023 Q3	$770K	Hold	50,621	–	–	0.02%	776
2023 Q2	$654K	Sell	50,621 -125,330	-71%	-$1.36M	0.02%	839
2023 Q1	$1.46M	Hold	175,951	–	–	0.04%	629
2022 Q4	$1.63M	Sell	175,951 -50,000	-22%	-$182K	0.04%	612
2022 Q3	$147K	Sell	225,951 -28,601	-11%	-$34.4K	﹤0.01%	1203
2022 Q2	$270K	Buy	254,552 +132,222	+108%	+$187K	0.01%	1019
2022 Q1	$248K	Buy	+122,330	New	+$320K	﹤0.01%	1128
2021 Q2	–	Sell	-35,000	Closed	-$389K	–	1340
2021 Q1	$389K	Buy	+35,000	New	+$427K	0.01%	1166

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Bridgeway Capital Management's CABA Position: Q2 2026 in Review

Bridgeway Capital Management held its Cabaletta Bio (CABA) position steady in Q2 2026 at 267,372 shares worth $832K. The position accounts for 0.01% of the portfolio, ranked #769.

Bridgeway Capital Management first reported a position in CABA in Q1 2021 and has held it in 16 quarters since. The position peaked at $1.63M in Q4 2022. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Bridgeway Capital Management held 267,372 shares of Cabaletta Bio worth $832K as of Q2 2026.
Bridgeway Capital Management left its Cabaletta Bio share count unchanged in Q2 2026.
Cabaletta Bio made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #769 holding.
Bridgeway Capital Management first reported a position in Cabaletta Bio in Q1 2021 and has held it in 16 quarters since.
Bridgeway Capital Management's Cabaletta Bio position peaked at $1.63M in Q4 2022.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.